Prof. Eric Raymond Oncologie Medicale

16 Seguidores

38 SlideShares 16 Seguidores 1 Siguiendo

Prof Eric Raymond is consultant, head of medical oncology at the Paris Saint-Joseph Hospital. Eric Raymond is board certified MD specialized in medical oncology and obtained a PhD degree in cellular and molecular biology, working on preclinical mechanisms of action and combinations of several novel anticancer drugs. He has been appointed as Chef de Clinique in Paris 6 Curie University with Prof. A. de Gramont for two years before undertaking a 2 year post-doctoral fellowship with Daniel D. Von Hoff at the Cancer Therapy and Research Center and Institute for Drug Development at the University of Texas in San Antonio, USA, Then, Eric Raymond undertook clinical and translational research in...

cancer immunotherapy hepatocellular carcinoma hepatocarcinoma resistance to anti-angiogenic drug new drugs targeted therapy antiangiogenic agent neuroendocrine tumors drug development covid-19 sunitinib tgf-beta vegfr targeted agents pnet resistance to immunotherapy resistance to chemotherapy pancreas angiogenesis cancer du colon pancreatic adenocarcinoma oncology oncologie hépatocarcinome targeted agent c-met new drug tepotinib new target tumeur neuroendocrine bevacizumab pdgfr pd1 pdl1 chimiotherapie immunotherapie chirurgie hcc fgfr4 car-t cell sorafenib combination therapy cell signaling squamous cell carcinoma anal cancer hgf second line tissue slicer transgenic mice leukemia phase 1 resistance to radiotherapy clinical trial liver metastases chemotherapy mtor octobre rose pandemic medical oncology oncologist covid novel targets cancer du sein lingerie met inhibitor tivantinib crizotinib tgf-beta inhibitor vegfr inhibitors resistance to targeted agent her3 her2 precision medicine lanreotide everolimus novel drugs anti-oncogene men1 somatuline biomarkers net preclinical models biotechnoligy parp inhibitor treatment of pancreatic cancer transcription nut otx-015 lymphoma jq1 breast cancer neuroblastoma prostate cancer bromodomain inhibitor otx015 nmc transcription reader bromodomain brca cancérologie maladies carciovasculaires relations franco chinoises ipilimumab yvon taillandier liver cancer primary liver malignancy galunisetib prevention cancer therapy innovative therapy nivolumab hospital managment blu-554 cancer mortality outbreak regorafenib moratlity checkpoint inhibitor signaling inhibitors vhl microenvironment endocrine malignancies somatostatin receptor ssa inssurance acreditation inca multimodality therapy liver-directed therapy genetics galunisertib small molecule translational research research hématologie healthcare interventional radiology surgery fgf19 met-inhibitor saint-joseph nab-paclitaxel folfirinox locally advanced borderline operable gemcitabine maquillage multidisciplinarité coiffure chimioembolisation recettes smoothies carcinose danse murine model sophrologie manucure conditional survival cancer breast cancer survival risk management biopsy cholangiocarcinoma pricing medicine toxicity safety solid tumor hormonothérapie intervention chirurgicale therapie ciblee humanized hospital rehabilitation prehabilitation hormonotherapy hpv18 hpv16 imaging immunodeficiency patient selection human immunodeficiency virus prognostic factor pet-scaning hiv first line suntinib hif1-alpha pancreatic phase 4 ex vivo models hypoxia mouse experiments antiangiogenics tumor resistance cancer du rectum intrapéritonéale pdgf vegf bio marqueurs sanguins cancer du foie notch human model cell lines cancer research cancer du rein head & neck cancer pf-03084014 methodology pharmacokinetic pharmacodynamic immunotherpy genetic background vaccination